Lumbar Facet Platelet-Rich Plasma Injection Versus Medial Branch Radiofrequency Ablation for Chronic Lumbar Facet-Mediated Pain
Not yet recruitingNot applicableNCT07692737
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The first clinical research effort under this initiative is a pilot randomized controlled trial comparing intra-periarticular lumbar facet platelet-rich plasma (PRP) injection to standard-of-care medial branch radiofrequency ablation (RFA) for chronic lumbar facet-mediated pain. The study is designed to: * Use contemporary best-practice techniques for both treatment arms * Minimize incremental risk beyond standard care * Generate feasibility, safety, and preliminary comparative effectiveness data * Inform future definitive trials and potential program expansion
Study details
- Official title
- A Randomized Controlled Trial Comparing Intra-Periarticular Lumbar Facet Platelet-Rich Plasma Injection Versus Medial Branch Radiofrequency Ablation for Chronic Lumbar Facet-Mediated Pain
- Conditions
- Chronic Lower Back Pain (CLBP)
- Lumbar Facet Joint Pain
- Interventions
- Procedure: Platelet Rich Plasma Joint Injection
- Procedure: Medial branch radiofrequency ablation
- Sponsor
- The New England Baptist Hospital
- Start date
- 2026-06
- Primary completion
- 2027-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults with chronic lumbar back pain suspected to be facet-mediated * ≥80% pain relief following two diagnostic medial branch blocks * Ability to provide informed consent * Ability to complete patient-reported outcome measures Exclusion Criteria: * Active radiculopathy or alternate dominant spinal pain generator * Prior lumbar fusion at target level * Active systemic infection or local infection at injection site * Thrombocytopenia, less than 100,000/uL * Anemia, Hemoglobin less than 10 g/dL * Pregnancy * Inability to complete follow-up assessments
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07692737